Open Nav

Please submit your session questions in advance at http://bit.ly/BIOCEO19question

Aquestive Therapeutics

  • Keith Kendall, Aquestive Therapeutics

Aquestive Therapeutics is a specialty pharmaceutical company committed to identifying, developing and commercializing differentiated products to address unmet medical needs. Aquestive Therapeutics has a late-stage proprietary product pipeline focused on the treatment of CNS diseases, and is working to advance orally-administered complex molecules that it believes can be alternatives to invasively-administered standard of care therapies. As the leader in developing and delivering drugs via its PharmFilm® technology, Aquestive Therapeutics also collaborates with pharmaceutical partners to bring new molecules to market in differentiated and highly-marketable dosage forms.

  • Date:Tuesday, February 12
  • Time:1:30 PM - 1:45 PM
  • Room:Herald/Soho
  • Location:7th Floor
  • Session Type:Company Presentation
  • Submission ID:23425
  • Company Presentation - Presentation Type:Publicly Traded Company
  • Goal for Presentation:Broaden Investor Outreach
  • Company Website:https://aquestive.com/
  • Company HQ City:Warren
  • Company HQ State:New Jersey
  • Company HQ Country:United States
  • Ticker:AQST
  • Exchange:NASDAQ
  • Main Therapeutic Focus:Platform for Therapeutics
  • Lead Product in Development:Libervant
  • Development Phase of Primary Product:NDA Preparation / In Review
Speakers
Keith Kendall
Aquestive Therapeutics
Back